Answers are grounded in this paper and cite their sources.
We present a case of a highly sensitized 54-year-old African American male with three prior failed transplants who received a zero mismatch deceased donor kidney and had antibody-mediated rejection directed against a human leukocyte antigen (HLA)-DP α donor-specific antigen. The donor was a 21-year-old man with normal renal function. The recipient's calculated panel reactive antibody was 99%. The standard anti-human globulin-enhanced T-cell and National Institute of Health (NIH) B-cell cytotoxicity crossmatches were negative. Flow cytometric B- and T-cell crossmatches were weakly positive by a few channels over the established cutoffs. Intraoperatively, 1 mg/kg antithymocyte globulin, 250 mg methylprednisolone, and 1 g/kg intravenous immunoglobulin (IVIG) were given. Postoperatively, an additional four daily doses of 1 mg/kg antithymocyte globulin, a tapering dose of steroids, and two doses of 500 mg/kg of IVIG were given. The recipient did not have delayed graft function but presented 2 weeks later with increased creatinine and oliguria. Biopsy revealed both borderline acute cellular and acute antibody-mediated rejection with diffuse C4d positivity in the peritubular capillaries on immunofluorescence. High-resolution HLA typing of the donor was pursued, and a mismatch at the DPA1 locus was identified. Single- antigen bead screening of pretransplant and posttransplant sera revealed a strong complement-fixing antidonor antibody (Luminex C1q antibody fixing assay, reference laboratory: Stanford University Blood Center Histocompatibility Laboratory) against DPA1*0103 with a titer by doubling dilution of 1/1024. The patient received high-dose steroids, multiple rounds of alternate day plasmapheresis, each followed by 100 mg/kg IVIG and 1 g rituximab. His antibody titers decreased to 1/64 and his creatinine nadired at 1.4 mg/dL. Six months later, he had another 1a cellular and chronic antibody-mediated rejection with a creatinine of 2.1 mg/dL. The United Network for Organ Sharing allocates zero-mismatched kidneys based on six antigens derived from the paired loci A, B, and DR encoded by the major histocompatibility complex located on chromosome 6. The rationale for this policy is improved graft survival in the setting of a more favorable immunologic environment. High-resolution HLA typing is not routinely performed for renal transplantation, and thus, DP status is usually unknown. DPA1 and DPB1 are similarly polymorphic as A, B, and DR, and as of January 2010, they have 28 and 138 known alleles, respectively (1). DP antigens were discovered in 1980 in restimulation experiments of previously primed T cells. They belong to HLA class II major histocompatibility complex and are composed of polymorphic α and β chains of similar molecular weight (32 kDa). They are characterized by weak primary allogeneic proliferative response but strong secondary cell- mediated cytotoxicity (2). HLA DP mismatches do not influence first kidney transplants but significantly impact outcomes for retransplants (3–5). It has been shown that donor-recipient pairs matched at A, B, and DR have a greater than 80% probability of being mismatched at DP loci (6, 8). We pursued DP typing for the donor, and our pair was matched at A, B, Cw, DR, and DQ alleles as determined by high-resolution (allele level) DNA sequence-specific priming typing (Table 1). The pretransplant sera of recipient contained a strong antidonor antibody against the donor's DPA1*0103 allele, with a mean fluorescence intensity in the range of 8000 to 14,000. An additional mismatch at DPB1*0601 was revealed and studied, but the antibodies against this allele were found to have mean fluorescence intensity less than 1000.TABLE 1: Our donor and recipients' typing by high-resolution DNA sequence-specific priming methodClinically significant antidonor antibodies to DPB1 have been associated with rejection in both variably matched and zero-mismatched renal allografts (7–9). In addition, antibodies to DPB1 have also been implicated in chronic humoral rejection in retransplants and have been found to share epitope with other HLA molecules (10). Further epitope classification of DPB1 has been pursued, which has helped in the identification of antibodies directed against them (11). It is known that failed renal allografts can elicit an antibody response to DP α (12). However, rejection related to antibodies to DPA1 has not been described previously, and our case is unique as it is the first one to report antibody-mediated rejection because of a high-strength antibody to DPA1. It is logical to think that incorporating appropriate donor and recipient HLA-Cw and DP antigens/alleles and antibody information using luminex solid phase assays into UNetSM would improve concordance between the virtual crossmatching being used for kidney allocation and the actual flow crossmatches. For zero-mismatched grafts, Cw concordance is likely, whereas DP is not. We think that the data forming the basis for virtual crossmatch should mirror today's laboratory capabilities and include all identifiable HLA specificities to provide accurate information on the potential for rejection. ACKNOWLEDGMENTS The authors thank Anthony Nizio, M.S., A.S.C.P. from the Immunogenetics and Tissue Typing Laboratory at Thomas Jefferson University Hospital for technical support. They also thank Dr. Jar-how Lee (Vice President, Research and Development) at One Lamda Inc., Canoga Park, CA, for assistance with analysis on noncommercially available DPB1 beads. Pooja Singh1 Beth W. Colombe1 George C. Francos1 Maria P. Martinez Cantarin1 Adam M. Frank2 1 Department of Medicine Thomas Jefferson University Philadelphia, PA 2 Department of Surgery Thomas Jefferson University Philadelphia, PA
No takes yet. Share an insight, caveat, or question.
Singh et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: